<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">Antiphospholipid syndrome</z:e> is characterized by the presence of <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo>, <z:hpo ids='HP_0100724'>hypercoagulability</z:hpo>, and prolonged <z:chebi fb="0" ids="16247">phospholipid</z:chebi>-dependent coagulation indices such as activated clotting time (ACT) </plain></SENT>
<SENT sid="1" pm="."><plain>Perioperative thrombotic complications are frequent among patients with <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> submitted to cardiac surgery, therefore, in these patients, <z:chebi fb="5" ids="28304">heparin</z:chebi>-protamine titration for anticoagulation monitoring is particularly recommended </plain></SENT>
<SENT sid="2" pm="."><plain>We demonstrate a case of 42-year-old hemodialyzed patient with <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e>, submitted to the replacement of stenotic aortic valve </plain></SENT>
<SENT sid="3" pm="."><plain>In our patient celite ACT and <z:chebi fb="5" ids="28304">heparin</z:chebi> concentration during cardiopulmonary bypass did not correspond to each other </plain></SENT>
<SENT sid="4" pm="."><plain>Anticoagulation based on <z:chebi fb="5" ids="28304">heparin</z:chebi> concentration assessment resulted in safe perioperative hemostatic management </plain></SENT>
</text></document>